Trial Information
Has the Quota of Signet Ring Cells an Influence on Prognosis and Treatment Strategy in the Upper GI Tract Adenocarcinomas?
stomach cancer signet ring cell carcinoma prognosis chemotherapy
Inclusion Criteria:
- All consecutive patients taken care of, for a proven histologically adenocarcinoma
(ADCI and ADNCI) of the esophagus, the esogastric junction, or the stomach, in
surgical or medical oncology investigator centers, will be saved in a given database.
- For whom the first consultation took place between January 1997 and January 2010
- As they benefit from a medical and/or surgical support (primitive cancer being or not
resected), whatever the metastatic or the recurrence situation was.
Exclusion Criteria:
- Histological type other than adenocarcinoma
- Other localization than esogastric junction, esophagus or stomach
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Retrospective
Outcome Measure:
To test the hypothesis that 5-year survival rate is significantly lower in the signet ring cells (SRC) adenocarcinoma when compared to non-SRC adenocarcinoma in the upper digestive tract
Outcome Time Frame:
participants are followed until death or time point at 31 september 2010
Safety Issue:
No
Principal Investigator
christophe mariette, MD, PhD
Investigator Role:
Study Director
Investigator Affiliation:
CHU lille
Authority:
France: National Consultative Ethics Committee for Health and Life Sciences
Study ID:
ADCI001
NCT ID:
NCT01249859
Start Date:
March 2010
Completion Date:
December 2010
Related Keywords:
- Signet Ring Cell Carcinoma
- Stomach Disease
- Oesophagus
- Prognostic
- Case-control Study
- stomach disease
- signet ring cell carcinoma
- chemotherapy
- Prognostic
- Carcinoma
- Stomach Diseases
- Carcinoma, Signet Ring Cell